Summary Information

Classification Chemicals / Complex Chemical Agents / Type:

(This chemicals section is currently predominantly used in Wildpro to link different data types and demonstrate inter-relationships. It does not contain detailed information on the chemical itself.)

Alternative Names cis-N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-2-quinolylcarbonyl-L-asparaginyl]-amino]butyl]-(4aS–8aS)-isoquinoline-3(S)-carboxamide
methane sulfonate; Invirase®, Fortovase®. (J549.30.w1)
Notes Information in this page has been entered to support the current volumes of Wildpro and further information will be added as new volumes are completed. This page is not intended to substitute for the manufacturer's data sheet and the information is not yet complete for all species, or for all contra-indications etc.

CAUTION: Before any pharmaceutical product is used, the manufacturer's data sheet, containing information on uses, dosage and administration, contra-indications, warnings etc., should always be consulted. It is important to remember that licensing of pharmaceutical products for use in a particular species/condition, as well as mandatory meat and milk withdrawal times for food-producing animals, varies between countries and changes with time. Withdrawal times also may vary between different pharmaceutical formulations and depending on route of administration. In the EU, the prescription cascade must be followed (see LCofC1.2H and W564.Apr05.w1); note that specific restrictions apply for food-producing animals. In the USA, FARAD may be consulted regarding residues and meat and milk withdrawal times.

  • Active against HIV-1 and HIV-2. (J549.30.w1)
  • Saquinavir is a protease inhibitor. These agents reduce the efficiency with which HIV-infected cells process viral proteins. Viral particles budding from infected cells treated with these agents are immature and non-infectious. (B560.14.w14)
  • As with other drugs active against HIV, mutations are selected which confer resistance. (B560.14.w14)
  • Used in the treatment of HIV-1 infection, in combination with other drugs. (J549.30.w1)
  • Several side-effects can occur with use of these drugs. (B574.69.w69)

Return to Top of Page